Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 777-784

  Liang, Yayun ^a   Besch Williford, Cynthia ^b   Benakanakere, Indira ^a   Hyder, Salman M ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Breast cancer; Estrogen; Nude mice; p53; PRIMA 1

Indexed keywords

2,2 BIS(HYDROXYMETHYL) 1 AZABICYCLO(2,2,2,)OCTAN 3 ONE; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; ESTROGEN RECEPTOR; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETICS; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; METABOLISM; MOUSE; MUTATION; NEOPLASM; NUDE MOUSE; PATHOLOGY;

ANIMALS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BREAST NEOPLASMS; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35848941495     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.777     Document Type: Article

References (33)

1. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
2. Barnes DM and Camplejohn RS: p53,apoptosis, and breast cancer. J Mammary Gland Biol Neoplasia 1: 163-175, 1996.
3. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
4. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J and Lane DP: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 46: 1839-1844, 1990.
5. Gewirtz DA: Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat 62: 223-235, 2000.
6. Bottini A, Berruti A, Bersiga A, et al: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000.
7. Rahko E, Blanco G, Soini Y, Bloigu R and Jukkola A: A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 39: 447-453, 2003.
8. Muller M, Wilder S, Bannasch D, et al: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045, 1998.
9. Bykov VJ, Issaeva N, Shilov A, et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288, 2002.
10. Liang Y, Wu J and Hyder SM: p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 93: 173-182, 2005.
11. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
12. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
13. Rubenstein LV, Shoemaker RH, Paull KD, et al: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
14. Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anti-cancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990. (Pubitemid 20213250)
15. El Etreby MF and Liang Y: Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 49: 109-117, 1998. (Pubitemid 28279588)
16. Lewis JS, Cheng D and Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 90: 944-949, 2004. (Pubitemid 38495809)
17. Dummer R, Bergh J, Karlsson Y, et al: Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 7: 1069-1076, 2000. (Pubitemid 30483487)
18. Cristofanilli M, Krishnamurthy S, Guerra L, et al: A non-replicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107: 935-944, 2006. (Pubitemid 44291141)
19. Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH and Cheng S: The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239: 617-620, 1997. (Pubitemid 27489014)
20. Liu G, Schwartz JA and Brooks SC: p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem Biophys Res Commun 264: 359-364, 1999. (Pubitemid 29516092)
21. Liu W, Konduri SD, Bansal S, et al: Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281: 9837-9840, 2006.
22. Diel P: Tissue-specific estrogenic response and molecular mechanisms. Toxicol Lett 127: 217-224, 2002.
23. Liang Y, Brekken RA and Hyder SM: VEGF induces proliferation of breast cancer cells and counteracts the anti-proliferative activity of anti-hormones. End Related Cancer 13: 905-919, 2006.
24. Mukhopadhyay D, Tsiokas L and Sukhatme VP: A Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
25. Nishizaki M, Fujiwara T, Tanida T, et al: Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5: 1015-1023, 1995.
26. Gustafsson JA and Warner M: Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 74: 245-248, 2000.
27. Matthews J and Gustafsson JA: Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3: 281-292, 2003.
28. Pearce ST and Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50: 3-22, 2004.
29. Bardin A, Boulle N, Lazennec G, Vignon F and Pujol P: Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 1: 537-551, 2004.
30. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A and Gustafsson JA: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66: 11207-11213, 2006.
31. Hyder SM, Nawaz Z, Chiappetta C and Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190, 2000.
32. Hall JM and McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578, 1999.
33. Chang EC, Frasor J, Komm B and Katzenellenbogen BS: Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147: 4831-4842, 2006.